StockData
Castle Biosciences Inc logo

Castle Biosciences Inc (CSTL) stock

CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/304% below fair value
$32.98+0.23 (+0.70%)

Close on Nov 17, 2026Market cap $1.01BP/E –Yield 0.00%

Castle Biosciences price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Castle Biosciences's price to sales ratio was 2.9× on Nov 11, 2026, against 3.4× a year earlier. Over the last 5 years it ranged from 1.3× to 12.7×, with a median of 2.9×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20262.9×−0.4
2025Dec 31, 20253.3×+0.9
2024Dec 31, 20242.4×−0.6
2023Dec 29, 20233.0×−2.0
2022Dec 30, 20225.0×−7.5
2021Dec 31, 202112.6×−8.6
2020Dec 31, 202021.2×+8.3
2019Dec 31, 201912.9×–

More Castle Biosciences figures

See a number that looks wrong?